Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan dose optimization for H. pylori eradication (bismuth quadruple therapy)
ChiCTR2200057697Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan in Helicobacter pylori infection (3 arms), sponsored by Beijing Hospital. Primary endpoint: Eradication rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200057697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057697.